Last update 01 Nov 2024

CD64 x α-synuclein x APP x PRNP

Basic Info

Related Targets
CD64α-synucleinAPP[+1]

Related

1
Drugs associated with CD64 x α-synuclein x APP x PRNP
NPT-088
Target
APP x CD64 x PRNP x α-synuclein
Mechanism
APP inhibitors [+4]
Active Org.
Proclara Biosciences, Inc.Proclara Biosciences, Inc.
Originator Org.
Proclara Biosciences, Inc.Proclara Biosciences, Inc.
Active Indication
Parkinsonian Disorders
Inactive Indication
Alzheimer Disease
Drug Highest PhasePhase 1
First Approval Ctry. / Loc.-
First Approval Date20 Jan 1800
1
Clinical Trials associated with CD64 x α-synuclein x APP x PRNP
NCT03008161 / CompletedPhase 1
A Phase 1 Randomized, Double-Blind, Placebo-Controlled, Multiple Dose, Dose Escalation Study of NPT088 in Patients With Probable Alzheimer's Disease
100 Clinical Results associated with CD64 x α-synuclein x APP x PRNP
Login to view more data
100 Translational Medicine associated with CD64 x α-synuclein x APP x PRNP
Login to view more data
0 Patents (Medical) associated with CD64 x α-synuclein x APP x PRNP
Login to view more data

Analysis

Perform a panoramic analysis of this field.
login
or
view full example data
Perform a panoramic analysis of this field.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free